The decision to back away from the development program for TC-5214 in major depression, partnered with AstraZeneca PLC, puts more pressure on Targacept Inc.’s remaining neuronal nicotinic receptor modulator programs; it is the second failure for an NNR drug partnered by the two companies.
The firms announced March 20 that they are ceasing pursuit of approval of TC-5214 for major depressive disorder following another...